Recent Updates
Recently added Catalysts
CHRS Neutral Sentiment Score: 55/100

Preliminary Revenues and Cash ©2025 Coherus BioSciences 39 2024 Total Year Expected Net Revenues $255M- $260M Cash, Cash Equivalents & Investments Q4 expected net revenues $49M-$54M OBI and strong pricing continue t

Monday, January 13, 2025 1 min read
Key Takeaway: Coherus BioSciences is anticipating total net revenues between $255 million and $260 million for the year 2024, with quarterly revenues expected to range from $49 million to $54 million in Q4. The release of the full financial results is scheduled for March 2025. The company plans to divest its UDENYCA Franchise and repay $230 million in convertible notes due in 2026. However, these transactions are contingent upon several conditions, including shareholder approval and regulatory clearances.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expected net revenues for 2024 projected to be between $255M-$260M.
  • Q4 expected net revenues range from $49M-$54M, indicating positive growth.
  • The company anticipates strong pricing and continuing sales from OBI.

CONCERNS & RISKS

  • Dependence on shareholder approvals for proposed transactions could delay progress.
  • Closing of transactions is contingent on various regulatory and customary conditions.

Full Press Release Details

The complete Coherus Fourth Quarter and Full Year 2024 Financial Results are planned for release in March 2025. The closing of all the proposed transactions, including the divestiture of the UDENYCA Franchise and repayment of the entirety of the company's $230 million convertible notes due April 2026, are subject to various conditions, including customary closing conditions, approval by Coherus shareholders, expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, any required approval by the Committee on Foreign Investment in the United States (CFIUS) as well as certain other conditions.

Frequently Asked Questions

When will Coherus release Q4 and full year 2024 financial results?

Coherus plans to release its financial results in March 2025.

What transactions are planned by Coherus?

Coherus plans to divest the UDENYCA Franchise and repay $230 million in notes.

What conditions must be met for Coherus transactions?

Transactions are subject to shareholder approval and antitrust review.

What is the deadline for Coherus' $230 million convertible notes?

The convertible notes are due in April 2026.

What regulatory approvals are needed for Coherus’ plans?

Approval from CFIUS and other necessary conditions is required.

Tags: CHRS Viatris Investor Conferences Healthcare Coherus BioSciences 2024 revenues UDENYCA Franchise financial results
Last updated: Jan 13, 2025